Abaxis to Report Fourth Quarter Fiscal 2008 Financial Results Thursday, May 1, 2008

Friday, May 2, 2008 General News J E 4
UNION CITY, Calif., April 28 Abaxis, Inc.(Nasdaq: ABAX), a medical products company manufacturing point-of-care bloodanalysis systems, has scheduled a conference call to discuss its financialresults for the fourth quarter of fiscal year 2008, ended March 31, 2008. Thecall will be at 4:15 p.m. ET on Thursday, May 1, 2008.

Participants can dial (877) 356-5706 or (706) 643-0580 to access theconference call, or can listen via a live Internet web cast, which can befound at under the Investor Relations tab. A replay ofthe call is available by visiting for the next 30 daysor by calling (800) 642-1687 or (706) 645-9291, access code 43094780, throughMay 4, 2008.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systemsfor use in any veterinary or human patient-care setting to provide clinicianswith rapid blood constituent measurements. The system consists of a compact,5.1 kilogram (11.2 pounds), portable analyzer and a series of single-useplastic discs, called reagent discs that contain all the chemicals required toperform a panel of up to 13 tests on veterinary patients and 14 tests on humanpatients. The system can be operated with minimal training and performsmultiple routine tests on whole blood, serum or plasma samples. The systemprovides test results in less than 12 minutes with the precision and accuracyequivalent to a clinical laboratory analyzer.Contact: Clint Severson Lytham Partners, LLC Chief Executive Officer Joe Dorame, Joe Diaz & Robert Blum Abaxis, Inc. 602-889-9700 510-675-6500

SOURCE Abaxis, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
CoreSpine Technologies Expands Spinal Disc Site Pr...
EUSA Pharma Divests Monoclonal Antibody Research B...